Akebia Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Akebia Therapeutics

30/10/2023 12:37

* Akebia Therapeutics Inc  AKBA.OQ   AKBA.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The Cambridge Massachusetts-based  company is expected to
report
 a 1.6% decrease in revenue to $48.183 million from $48.96
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Akebia Therapeutics
Inc
is for a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akebia
Therapeutics Inc is $3.88​, above​ its last closing price
of $0.84. ​​​

This summary was machine generated October 30 at 12:37 GMT.  All
figures in US dollars  unless otherwise stated